TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25169119
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PCT) - docetaxel, cisplatin, 5-FU
Study: 25169119
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PCT)
Study: 21493739
Drug: Warfarin (low-intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (low-intensity monitored-dose, target INR 1.5 to 1.9)
Study: 14690568
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 + NS 100 ml or 200 ml (Group A)
Study: 14690568
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 + Cisplatin 30 mg/m2 (Group B)
Study: 14690568
Drug: Imported Gemzar
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported Gemzar + Cisplatin 30 mg/m2 (Group C)
Study: 14690568
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 (Group B)
Study: 10768309
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) at a mean dosage of 29 mg/kg/day, maximum dosage of 50 mg/kg/day, for a mean duration of 18 months.
Study: 6376485
Drug: Isocarboxazid (40-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocarboxazid (40-50 mg/day)
Study: 28941006
Drug: 5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg/kg palonosetron
Study: 26795844
Drug: 10 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/kg palonosetron
Study: 24447683
Drug: α-glucosidase inhibitor
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-glucosidase inhibitor (αGI)
Study: 9113940
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg once daily)
Study: 3890504
Drug: Cimetidine, 300
Normalized name: Cimetidine, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 300 mg orally every 6 hours
Study: 30044959
Drug: Allogeneic umbilical
Normalized name: Allogeneic umbilical cord mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic umbilical cord-derived mesenchymal stem cells (MSCs) at doses of 1 × 10^6 cells/kg, 2 × 10^6 cells/kg, and 3 × 10^6 cells/kg
Study: 22289995
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (HD-DXM) 40 mg/day for 4 consecutive days
Study: 20216531
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment targeting parents' responses and children's coping (3 sessions)
Study: 12570912
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy at an initial dose of 0.125 IU/Kg/week followed by 0.250 IU/Kg/week
Study: 12212211
Drug: Full-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose aprotinin (Group A, n = 10)
Study: 1390529
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of cefuroxime (125 mg)
Study: 1390529
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of both cefuroxime and Betnesol (betamethasone sodium phosphate 0.1%)
Study: 4056964
Drug: Restrictive diets
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive diets based on oral food challenge results
Study: 3475553
Drug: Double-blind placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind placebo-controlled oral food challenges
Study: 30392239
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg daily from day 1 to 14 of a 21-day cycle)
Study: 20457982
Drug: No initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No initial treatment (control group)
Study: 10527711
Drug: Liquid shark
Normalized name: shark preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid shark cartilage extract (7 ml)
Study: 10527711
Drug: Liquid shark
Normalized name: shark preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid shark cartilage extract (21 ml)
Study: 7138750
Drug: Cimetidine (oral)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (oral) for 2 months
Study: 7138750
Drug: Cimetidine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (intravenous infusion) for 48 hours
Study: 26625755
Drug: High onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High onion group (HO; n=28) - 100-160 g/d of fresh yellow onion for 8 weeks
Study: 26625755
Drug: Low onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low onion group (LO; n=28) - 30-40 g/d of small onion for 8 weeks
Study: 21856592
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam HCl (3.75 g/d)
Study: 12969093
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ropivacaine HCl rectally in 20 mL hydroxypropyl methylcellulose gel
Study: 12969093
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ropivacaine HCl rectally in 40 mL hydroxypropyl methylcellulose gel
Study: 12969093
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ropivacaine HCl rectally in 60 mL hydroxypropyl methylcellulose gel
Study: 12969093
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ropivacaine HCl rectally in 80 mL hydroxypropyl methylcellulose gel
Study: 11121911
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy based on rabeprazole (20 mg b.d.), clarithromycin (250 mg t.d.s.), and amoxicillin (500 mg t.d.s.)
Study: 11121911
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy based on rabeprazole (20 mg b.d.), clarithromycin (250 mg t.d.s.), amoxicillin (500 mg t.d.s.) supplemented with a lyophilized and inactivated culture of Lactobacillus acidophilus (t.d.s.)
Study: 9360784
Drug: G-CSF mobilized
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF mobilized PBSC
Study: 9360784
Drug: G-CSF vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF vs. GM-CSF
Study: 3870624
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg)
Study: 12654171
Drug: Marine oil
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine oil (MO) 600 mg/d providing 150 mg DHA + 30 mg EPA for 6 weeks
Study: 12654171
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg sunflower oil/d)
Study: 11165585
Drug: Elevated umbilical
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated umbilical venous cord blood plasma IL‐6 concentrations (≥10 pg/mL)
Study: 11165585
Drug: Normal umbilical
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal umbilical venous cord blood plasma IL‐6 concentrations (<10 pg/mL)
Study: 9553402
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral supplementation with vitamin C, E, and beta-carotene for 21 days
Study: 7997808
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TPS and CA 125
Study: 7997808
Drug: TPS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPS and CA 125 during therapy and follow-up
Study: 3041630
Drug: aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: aqueous procaine penicillin G (APPG) with 1 g of oral probenecid
Study: 25381047
Drug: Zoledronate (ZOL)
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate (ZOL) 4 mg intravenous every 3 months for 24 months
Study: 15658645
Drug: Tongguan capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongguan capsule (TGC) with Western medicine
Study: 11320886
Drug: Combined preoperative
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preoperative radiochemotherapy with hyperthermia (Radiotherapy: 5 x 1.8 Gy up to 45 Gy; Chemotherapy: 5-Fluorouracil 300-350 mg/m2/d and Leucovorin 50 mg; Hyperthermia: SIGMA 60 applicator BSD 2000 once a week).
Study: 30706488
Drug: Kiwifruit (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kiwifruit (two kiwifruits twice daily for 3 days)
Study: 30706488
Drug: Control (isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isocaloric maltodextrin, twice daily for 3 days)
Study: 22981147
Drug: LB80380 maleate
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB80380 maleate formulation (183 mg tablet)
Study: 22981147
Drug: LB80380 free
Normalized name: Free Cysteine
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LB80380 free base formulation (60 and 90 mg tablets)
Study: 17888191
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg kg(‐1) propofol followed by 8% sevoflurane
Study: 14649346
Drug: Meperidine 1
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 1 mg kg(‐1)
Study: 10067708
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine candidates (e.g., live preparations, DNA plasmids)
Study: 8612313
Drug: Uracil plus
Normalized name: uracil
DrugBank: Uracil (DB03419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uracil plus ftorafur (UFT) at 350 mg/m2 plus leucovorin (150 mg daily)
Study: 24525393
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g twice daily for 12 weeks
Study: 12116830
Drug: Subcutaneous digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous digital block
Study: 12116830
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of modified transthecal and subcutaneous digital block
Study: 17137546
Drug: Amoxicillin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (7 days)
Study: 31400933
Drug: PGC preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGC preparation
Study: 22511495
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (800 mg/day for 6 months) followed by standard-dose imatinib (400 mg/day)
Study: 20547287
Drug: STI-positive adolescents
Normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STI-positive adolescents who received treatment and counseling
Study: 17977537
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ferrous sulfate daily
Study: 11374853
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy including aggressive lipid control
Study: 1448776
Drug: Recombinate (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinate (recombinant FVIII preparation)
Study: 25116967
Drug: Calcitriol ointment
Normalized name: Calcitriol Ointment
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol ointment (3 mcg/g)
Study: 25116967
Drug: Betamethasone diproprionate
Normalized name: betamethasone 0.05 % (betamethasone diproprionate 0.64 MG/ML) Augmented Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone diproprionate ointment (64 mg/g)
Study: 21756141
Drug: Non-hydrolized carnosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hydrolized carnosine (Can-C Plus® formulation)
Study: 30642326
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical exercise programme (2 weekly sessions for 6 months, including at least 30 min of moderate intensity activity)
Study: 30642326
Drug: Antidepressant drug
Normalized name: MAO A Inhibitors, antidepressant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant drug treatment (habitually used in clinical practice)
Study: 23085365
Drug: GMZ2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 vaccine in Trichuris trichiura negative subjects
Study: 23085365
Drug: GMZ2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 vaccine in Trichuris trichiura positive subjects
Study: 20518324
Drug: JEV-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JEV-L
Study: 2689255
Drug: trimoprostil 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimoprostil 750 micrograms taken 4 times daily
Study: 6108128
Drug: Flunitrazepam (0.25‐0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.25‐0.50 mg)
Study: 6108128
Drug: Triazolam (0.25‐0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25‐0.50 mg)
Study: 6108128
Drug: Brotizolam (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam (0.6 mg)
Study: 23414763
Drug: Moisturizing Durable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturizing Durable Barrier Cream (MDBC)
Study: 23414763
Drug: 10% Glycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Glycerine Cream (Sorbolene)
Study: 21812264
Drug: Guizhi Fuling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guizhi Fuling Capsule
Study: 19950299
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral MLN3897 once daily for 12 weeks while continuing to receive MTX once a week
Study: 19950299
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily for 12 weeks while continuing to receive MTX once a week
Study: 18722214
Drug: Intranasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroid injection (triamcinolone), 1 cc (20 mg/mL) injected into each inferior turbinate
Study: 18722214
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline), 1 cc injected into each inferior turbinate
Study: 15702061
Drug: Levobupivacaine Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine Group (L) 30 ml of 0.5% levobupivacaine
Study: 15702061
Drug: Levobupivacaine Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine Group (L)
Study: 8150762
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g i.v. bd
Study: 8150762
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g i.v. tds
Study: 11795430
Drug: Bowman-Birk Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowman-Birk Inhibitor Concentrate (BBIC)
Study: 30623534
Drug: Ropivacaine (7.5%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (7.5%, 5 mL)
Study: 28300812
Drug: placebo naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo naltrexone + guanfacine (NP+G)
Study: 22267280
Drug: pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pioglitazone (PIO) 30 mg once daily
Study: 22267280
Drug: metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin (MET) 1000 mg twice daily
Study: 20337077
Drug: Two-visit endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit endodontic treatment (calcium hydroxide as interappointment medicament)
Study: 17377528
Drug: Acetaminophen 4
Normalized name: acetaminophen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4 then 6 g/day
Study: 17377528
Drug: Acetaminophen 4
Normalized name: acetaminophen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4 then 8 g/day
Study: 11879108
Drug: Nonoxynol-9 gel
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 gel (100 mg) and condoms
Study: 10434239
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg twice daily)
Study: 8574711
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily plus Cisapride 20 mg twice daily
Study: 8574711
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily alone
Study: 2186273
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (100 U/kg thrice weekly by intravenous bolus)
Study: 25902327
Drug: Prophylactic oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic oxytocin infusion at 44.2 IU/h (ED90) in laboring women
Study: 25902327
Drug: Prophylactic oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic oxytocin infusion at 16.2 IU/h (ED90) in nonlaboring women
Study: 25902327
Drug: Requirement for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Requirement for additional uterotonic agents in laboring women
Study: 25902327
Drug: Requirement for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Requirement for additional uterotonic agents in nonlaboring women
Study: 17580734
Drug: Betaxolol, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol, 20 mg once daily
Study: 17580734
Drug: Metoprolol tartrate,
Normalized name: Metoprolol Tartrate, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol tartrate, 50 mg twice daily
Study: 15090020
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene 0.1% cream applied BID
Study: 8431341
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine 5 mg in saline 25 ml
Study: 8431341
Drug: Saline 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 25 ml intra-articularly (Control)
Study: 29166890
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion (CPM) in combination with early motion Physical Therapy (PT) supervised by a physical therapist
Study: 29166890
Drug: Early motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early motion Physical Therapy (PT) supervised by a physical therapist
Study: 29166890
Drug: Outpatient supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient supervised Physical Therapy (PT) from postoperative day seven till ten
Study: 26405670
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and systemic antibiotics
Study: 23955055
Drug: Both counseling
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both counseling and nicotine patch
Study: 18280205
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (1000mg)
Study: 17009270
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone (15 mg/kg of ideal body weight/day)
Study: 1950033
Drug: Lovastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 80 mg
Study: 31504554
Drug: GHB (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (50 mg/kg body weight)
Study: 28335841
Drug: ASV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASV plus optimized medical therapy (OMT)
Study: 23444286
Drug: Doxylamine/pyridoxine delayed-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine/pyridoxine delayed-release combination (Diclectin)
Study: 21148606
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (Group C)
Study: 2405737
Drug: 10 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms/kg atropine followed by 0.1 ml/kg 1% lidocaine with 1/200,000 epinephrine (0.5 micrograms/kg)
Study: 2405737
Drug: 0.1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml/kg 1% lidocaine with 1/200,000 epinephrine (0.5 micrograms/kg) without atropine
Study: 2405737
Drug: 10 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms/kg atropine followed by 0.1 ml/kg 1% lidocaine without epinephrine
Study: 2405737
Drug: 0.1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml/kg 1% lidocaine without epinephrine without atropine
Study: 6776586
Drug: Diazepam (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (moderate doses)
Study: 22105872
Drug: Standard-dose IVLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose IVLE (0.5 g kg(‐1) day(‐1) gradually increased to a maximum of 3.5 g kg(‐1) day(‐1))
Study: 22105872
Drug: Restricted-dose IVLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted-dose IVLE (1 g kg(‐1) day(‐1))
Study: 22105872
Drug: Standard-dose IVLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose IVLE
Study: 22105872
Drug: Restricted-dose IVLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted-dose IVLE
Study: 16032969
Drug: New divisible
Approvals — FDA: no, EMA: no, PMDA: no
Description: New divisible formulation of lamotrigine (100 mg)
Study: 16032969
Drug: Plain lamotrigine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain lamotrigine tablet
Study: 16032969
Drug: Dispersible/chewable lamotrigine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible/chewable lamotrigine tablet
Study: 7571982
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (ascites and very low sodium excretion)